Human VEGF R2/KDR Quantikine ELISA Kit | hVEGF R2 Qkit
掲載日情報：2016/08/18 現在Webページ番号：111231
R&D Systems製のHuman VEGF R2/KDRを測定するELISAキットです。
※本製品は研究用です。研究用以外には使用できません。
[在庫・価格 ：2024年06月01日 20時55分現在]
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Flk-1, Human, ELISA Kit, Quantikine (96well) <VEGF Receptor 2, ELISA Kit> |
|
42 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 ：2024年06月01日 20時55分現在]
Flk-1, Human, ELISA Kit, Quantikine (96well) <VEGF Receptor 2, ELISA Kit>
文献数： 42
- 商品コード：DVR200
- メーカー：RSD
- 包装：1kit
- 価格：¥116,000
- 在庫：無(未発注)
- 納期：10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 |
測定範囲：78.10 - 5000 pg/mL，感度：11.4 pg/mL，測定試料：Cell Culture Supernates (100 uL), Cell Lysates (100 uL), Serum (20 uL), EDTA Plasma (20 uL), Heparin Plasma (20 uL)，種交差性：Human，検出方法：colorimetric，測定波長：450 nm，アッセイ法：Solid Phase Sandwich ELISA，アッセイ数：96，別売品コントロール：QC05，測定時間：4.5 hours，測定因子：VEGFR2/KDR/Flk-1 別名：CD309 Genbank No： 3791 |
||||||
|---|---|---|---|---|---|---|---|
| 別包装品 | 別包装品あり | ||||||
| 法規制等 | |||||||
| 保存条件 | 4℃ | 法規備考 | |||||
| 掲載カタログ |
|
||||||
| 製品記事 |
ELISA Kit製品に関するFAQ（R&D Systems） |
||||||
| 関連記事 |
R&D Systems Quantikine ELISA Kit／DuoSet Kit特集 |
||||||
追加しました。
Product Details
- Assay Type
- Solid Phase Sandwich ELISA
- Format
- 96-well strip plate
- Assay Length
- 4.5 hours
- Sample Type & Volume Required Per Well
- Cell Culture Supernates (100 µL), Cell Lysates (100 µL), Serum (20 µL), EDTA Plasma (20 µL), Heparin Plasma (20 µL)
- Sensitivity
- 11.4 pg/mL
- Assay Range
- 78.1 - 5,000 pg/mL (Serum, Heparin Plasma, Cell Culture Supernates, Cell Lysates, EDTA Plasma)
- Specificity
- Natural and recombinant human VEGF R2
- Interference
- Interference observed with 1 or more available related molecules.
追加しました。
Product Summary
The Quantikine Human VEGF R2 Immunoassay is a 4.5 hour solid-phase Immunoassay designed to measure human soluble VEGF R2 in cell culture supernates, cell lysates, serum, and plasma. It contains NS0-expressed recombinant human VEGF R2/Fc Chimera and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human VEGF R2 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human soluble VEGF R2.
追加しました。
Precision
Intra-Assay Precision (Precision within an assay)
Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays)
Three samples of known concentration were tested in separate assays to assess inter-assay precision.
Cell Culture Supernates, Cell Lysates, Serum, EDTA Plasma, Heparin Plasma
| Intra-Assay Precision | Inter-Assay Precision | |||||
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 40 | 40 | 40 |
| Mean | 465 | 1,269 | 2,995 | 455 | 1,233 | 2,962 |
| Standard Deviation | 19.4 | 45.5 | 87.9 | 32.1 | 84.8 | 169 |
| CV% | 4.2 | 3.6 | 2.9 | 7 | 6.9 | 5.7 |
追加しました。
Recovery
The recovery of VEGF R2 spiked to levels throughout the range of the assay was evaluated.
| Sample Type | Average % Recovery | Range % |
| Cell Culture Media (n=4) | 99 | 92-104 |
追加しました。
Linearity
To assess the linearity of the assay, samples containing high concentrations of VEGF R2 were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
追加しました。
Additional Infomation
- Molecule Information
- VEGF R2/KDR/Flk-1
- Aliases
- CD309; Flk-1; KDR
- Entrez Gene IDs
- 3791 (Human); 16542 (Mouse)
- Background
- VEGF R2
- VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoieticdevelopment. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.
追加しました。
Citations
Citations of cell biology reagents in peer reviewed literature can be used as a direct measure of product quality. They can also provide crucial insightinto their use under specialized or unique experimental conditions. Because of the importance published citations have to researchers, R&D Systems personnelmanually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but alsoprovides information about sample types, species, and experimental conditions.
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
Br. J. Cancer 2012 107:639-45
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Adamson P, Balis F, Baruchel S, Blaney S, Burke M, Fox E, Glade Bender J, Ingle A, Kim A, Stempak D, Weigel B, Widemann B
Clin Cancer Res 2012 18:6011-22
Species: Human
Sample Type: Plasma
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
Billiot F, Escudier B, Farace F, Gross-Goupil M, Hill C, Jacques N, Mauguen A, Taylor M, Tournay E, Vimond N
Br. J. Cancer 2011 104:1144-50
Species: Human
Sample Type: Plasma
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Cremolini C, Fioravanti A, Loupakis F
Br. J. Cancer 2011 104:1262-9
Species: Human
Sample Type: Plasma
Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept.
Bekele BN, Camphausen K, Chen A, Cloughesy T, de Groot JF, Deangelis L, Gilbert M, Heymach JV, Lassman A, Liu J, Mehta M, Piao Y, Prados M, Robins HI, Tran H, Wen PY, Wu HK, Yung W
Clin. Cancer Res. 2011 17:4872-4881
Species: Human
Sample Type: Plasma
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
Adamson PC, Ahern CH, Baruchel S, Blaney SM, Dubois SG, Glade-Bender J, Grier HE, Ingle AM, Ivy P, Reid JM, Shusterman S, Wu B
Clin. Cancer Res. 2011 17:5113-22
Species: Human
Sample Type: Plasma
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Boucher E, Cheng AL, DePrimo SE, Douillard JY, Faivre S, Harmon CS, Kim JS, Lanzalone S, Lechuga MJ, Lim HY, Lin X, Raymond E
J Transl Med 2011 9:120
Species: Human
Sample Type: Plasma
Prognostic significance of angiogenic factors in uterine cervical cancer.
Blohmer JU, Heidecke H, Jeschke S, Korlach S, Kummel S, Landt S, Lichtenegger W, Schmid P, Sehouli J, Stoblen F, Wehling M
Anticancer Res. 2011 31:2589-95
Species: Human
Sample Type: Serum
Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis.
Adamyan L, Bourlev V, Iljasova N, Larsson A, Olovsson M
Fertil. Steril. 2010 94:52-7
Species: Human
Sample Type: Serum
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
Burger H, de Jonge MJ, Konings IR
Br. J. Cancer 2010 103:987-92
Species: Human
Sample Type: Serum
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。